Wilson Disease Drugs Market Trends

Growth Drivers

• Growing Prevalence of Wilson’s Disease in Young Population – Wilson’s disease generally occurs in the younger population since it is passed on to children by their parents and shows symptoms at an early age. The symptoms of Wilson’s disease include stomach aches, swelling, weariness, and others.  For instance, the most common age at which symptoms of this disease appears is 12 and 13.
• Escalating Trial on Gene Therapy – gene therapy is highly advantageous in treating Wilson’s disease since it transits the working ATP7B gene into cells that create working transporter proteins. For instance, around 90% of the trial of gene therapy were noticed to be in their early phases while 70% of the were conducted in 2018 in the United States.
• Increasing Health Spending across the Globe – based on the current expenditure data, global health spending has increased over the past 20 years, doubling in real terms to hit USD 8.5 trillion in 2019 and 9.8% of GDP, up from 8.5 percent in 2000.
• Growing R&D Expenditure for Clinical Trials – for instance, in 2021, more than 400,000 studies were noticed to be conducted in 200 countries across the globe.

Challenges

• High Treatment Costs and Lack of Reimbursement Facilities - Despite the presence of improved healthcare infrastructure, there is a high cost associated with these drugs which are used for the treatment of Wilson’s disease. In addition to this, the poor reimbursement policies in developing countries are estimated to hinder the growth of the Wilson’s disease drugs market in the future.
• Lack of Awareness in Low-Income Countries.
• Requirement for Higher Initial Investments